About Asterand Bioscience
Asterand Bioscience is a company based in Detroit (United States) founded in 2000 was acquired by BioIVT in August 2017. Asterand Bioscience has raised $7.11 million across 4 funding rounds from investors including Gov.uk, BioIVT and Stemgent. Asterand Bioscience operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Detroit, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Asterand Bioscience
Asterand Bioscience has successfully raised a total of $7.11M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Asterand Bioscience
Asterand Bioscience has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, BioIVT and Stemgent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm making investment in early & growth stage healthcare & tech companies in the US
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Locked | Locked | Locked |
Investor details for Asterand Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Asterand Bioscience
Investment portfolio details for Asterand Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Asterand Bioscience
Detailed financials for Asterand Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Asterand Bioscience Comparisons
Peer comparison for Asterand Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Asterand Bioscience
Asterand Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Asterand Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Asterand Bioscience
Complete news archive for Asterand Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asterand Bioscience
Asterand Bioscience was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Asterand Bioscience is headquartered in Detroit, United States. It is registered at Detroit, Michigan, United States.
Asterand Bioscience is a funded company, having raised a total of $7.11M across 4 funding rounds to date.
Asterand was formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. The companys XpressBANK biobank contains several hundred thousand specimens from a broad range of therapeutic areas and with diverse ethnic representation. Through its BioSPOKE service, human tissues and clinical data can also be custom collected to meet special requirements. Through its PhaseZERO drug discovery services platform, they provide a collaborative scientific approach to deliver human tissue-based data on target biomarker validation as well as compound potency, effect and safety. The studies can be custom designed and are conducted on a fee-for-service basis where clients own and retain all resulting IP and data.
Asterand Bioscience's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Asterand Bioscience has 8 investors. Key investors include Gov.uk, BioIVT, Stemgent, Chrysalis Ventures, and Apjohn Ventures.